Compare CDLR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDLR | SRPT |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2023 | 2000 |
| Metric | CDLR | SRPT |
|---|---|---|
| Price | $6.67 | $17.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $21.64 |
| AVG Volume (30 Days) | 97.6K | ★ 2.5M |
| Earning Date | 11-23-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $57.98 | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | $7.39 | ★ $6.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $14.68 |
| 52 Week High | $32.81 | $24.68 |
| Indicator | CDLR | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 18.71 | 45.22 |
| Support Level | N/A | $16.51 |
| Resistance Level | $25.23 | $18.45 |
| Average True Range (ATR) | 1.82 | 0.99 |
| MACD | -1.76 | -0.01 |
| Stochastic Oscillator | 0.42 | 21.06 |
Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.